Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stelara Settlement Gives Amgen US Ustekinumab Entry Date

Agreement With Johnson & Johnson’s Janssen Offers Amgen 1 January 2025 Launch Date

Executive Summary

A settlement reached in US patent litigation over Janssen’s Stelara will allow Amgen to launch its ABP 654 ustekinumab biosimilar no later than 1 January 2025. It remains to be seen whether other ustekinumab developers will follow suit.

You may also be interested in...



Francis Takes Stock Of Teva Ahead Of Revealing Fresh Strategy

As Teva prepares to unveil a fresh strategy under new CEO Richard Francis on 18 May, the company has delivered Q1 results along with an update on planned US launches for long-acting injectable risperidone as well as biosimilar adalimumab.

Amgen Reveals First Figures For US Humira Rival

As Amgen and AbbVie reveal first-quarter results, a clearer picture is beginning to emerge of the dynamics for biosimilar competition to Humira in the US. But Amgen is cautioning that Q2 sales of Amjevita may not match initial uptake in Q1.

Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry

Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel